Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 10:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 3,307 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard Oncology Care Clear all
Completed No phase listed Observational

M. D. Anderson Symptom Inventory - Ovarian Cancer

NCT01037751
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Interview, Survey
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 5, 2026, 10:51 PM EDT
Terminated No phase listed Observational

Freehand Ultrasound Elasticity Imaging in Liver Surgery

NCT00942383
View directory record Official record
Conditions
Liver Tumors
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 5, 2026, 10:51 PM EDT
Completed Phase 2 Interventional Results available

Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study

NCT01617629
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
MUC1 Dendritic Cell Vaccine (Cvac)
Biological
Lead sponsor
Prima BioMed Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Greenbrae, California • La Jolla, California • Boca Raton, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 5, 2026, 10:51 PM EDT
Not listed No phase listed Observational

Expressive Disclosure and Colorectal Cancer

NCT00853203
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Interviews, Questionnaires, Electronically Activated Recorder (EAR), Group Meetings, Written Materials
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 5, 2026, 10:51 PM EDT
Completed Not applicable Interventional

Preoperative Nutritional Intervention in Head and Neck Cancer

NCT03971656
View directory record Official record
Conditions
Head and Neck Cancer, Malnutrition
Interventions
Nutritional Supplement, Preoperative Dietitian Consult, Education
Dietary Supplement · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 5, 2026, 10:51 PM EDT
Completed Phase 2 Interventional

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

NCT04321954
View directory record Official record
Conditions
Differentiated Thyroid Cancer, Advanced Cancer
Interventions
LENVATINIB
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 5, 2026, 10:51 PM EDT
Active, not recruiting Early Phase 1 Interventional

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02659241
View directory record Official record
Conditions
Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Carcinomatosis, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Adavosertib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Portland, Oregon • Conroe, Texas • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 5, 2026, 10:51 PM EDT
Completed No phase listed Observational

Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents

NCT01737554
View directory record Official record
Conditions
Cancer, Hematologic Disorders
Interventions
Catheter Resistance Monitoring
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years to 24 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Oct 5, 2026, 10:51 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

NCT01204996
View directory record Official record
Conditions
Cancer
Interventions
CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection, CNTO888 + gemcitabine, CNTO888 + Paclitaxel and carboplatin, CNTO888 + docetaxel
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Detroit, Michigan • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Oct 5, 2026, 10:51 PM EDT
Completed Early Phase 1 Interventional

Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer

NCT03578224
View directory record Official record
Conditions
Esophagus
Interventions
Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA), Contrast-Enhanced Ultrasound, Fine-Needle Aspiration, Sonazoid (Perflubutane)
Procedure · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 5, 2026, 10:51 PM EDT
Active, not recruiting Phase 3 Interventional

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

NCT05477576
View directory record Official record
Conditions
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
Interventions
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
32
States / cities
Phoenix, Arizona • Duarte, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 5, 2026, 10:51 PM EDT
Terminated No phase listed Observational

A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide

NCT05414123
View directory record Official record
Conditions
Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer, Non-Small Cell Lung Cancer
Interventions
CNSide
Device
Lead sponsor
Biocept, Inc.
Industry
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Stanford, California • Chicago, Illinois • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 5, 2026, 10:51 PM EDT
Active, not recruiting Not applicable Interventional

A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer

NCT03561220
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of Care IMRT (Photon), Standard of Care Proton Therapy, Proton Arm 1: Standard Proton Therapy, Proton Arm 2: Hypofractionated Proton Therapy
Radiation
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 85 Years · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 5, 2026, 10:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Addressing Colorectal Cancer in South Florida Firefighters

NCT05976282
View directory record Official record
Conditions
Colorectal Cancer, CRC
Interventions
Fecal Immunochemical Test, Septin9 Test
Other
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 65 Years
Enrollment
646 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 5, 2026, 10:51 PM EDT
Recruiting Not applicable Interventional

Rehabilitation Outcomes Study

NCT06674889
View directory record Official record
Conditions
Cancer, Malignant Tumor
Interventions
Rehabilitation-based intervention
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 5, 2026, 10:51 PM EDT
Completed Phase 3 Interventional Results available

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

NCT03523585
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab deruxtecan, Capecitabine, Lapatinib, Trastuzumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
41
States / cities
Chandler, Arizona • Los Angeles, California • Monterey, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 5, 2026, 10:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

NCT04969315
View directory record Official record
Conditions
Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
Interventions
TT-10, TT-4
Drug
Lead sponsor
Portage Biotech
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 5, 2026, 10:51 PM EDT
Completed Not applicable Interventional

Scale Down for Endometrial Cancer

NCT03169023
View directory record Official record
Conditions
Endometrial Cancer, Cancer of the Endometrium
Interventions
ScaleDown, Enhanced Usual Care Packets, 12-Item Short Form Health Survey, International Physical Activity Questionnaire short form, Multidimensional Body Self Relations Questionnaire - Appearance Subscales, Cancer-Related Body Image Scale, Patient Health Questionnaire 9-Item Version, iOTA
Behavioral · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 5, 2026, 10:51 PM EDT
Active, not recruiting No phase listed Observational

Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations

NCT05687188
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Blood Sample Collection, Tissue Sample Collection, Data Collection, Medical Image Collection
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Tampa, Florida • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 5, 2026, 10:51 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Digital Breast Tomosynthesis + Standard 2- Dimensional Mammography in Breast Cancer

NCT03190083
View directory record Official record
Conditions
Breast Cancer
Interventions
2-dimensional mammogram, digital breast tomosynthesis (DBT)
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
25 Years to 85 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 5, 2026, 10:51 PM EDT
Recruiting Phase 3 Interventional

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089
View directory record Official record
Conditions
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions
Secretin, MRI, Tumor marker gene test with CA19-9
Drug · Diagnostic Test · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 5, 2026, 10:51 PM EDT
Active, not recruiting Phase 3 Interventional

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

NCT03949283
View directory record Official record
Conditions
Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Interventions
ChemoID Assay, Standard Chemotherapy
Diagnostic Test · Drug
Lead sponsor
Cordgenics, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 5, 2026, 10:51 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

NCT02516241
View directory record Official record
Conditions
Urothelial Cancer
Interventions
MEDI4736 (Durvalumab), Tremelimumab, Cisplatin, Carboplatin, Gemcitabine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
16
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 5, 2026, 10:51 PM EDT
Completed Not applicable Interventional

REJOIN Trial for Older Breast Cancer Survivors

NCT03955627
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN)
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 5, 2026, 10:51 PM EDT